Lonza and Eclipse Therapeutics Announce Development and Manufacturing Agreement for Lonza to Conduct Phase 1 Production of Eclipse’s ET-101
Lonza will manufacture ET-101 at its mammalian development and manufacturing facility in Slough, UK
Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor initiation, recurrence and metastasis. ET-101 is a novel therapeutic antibody designed to target these cancer stem cells. Eliminating cancer stem cells, in conjunction with other therapies that address the tumor bulk, represents a new cancer treatment paradigm that could offer a distinct advantage over existing strategies and a solution for chemoresistance.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.